Janssen is pushing hard for new approvals for the Genmab-developed cancer drug Darzalex which is being tested in a range of phase III studies. This year, the biotech expects data from a trial that could clear the product for front-line use against multiple myeloma and double the potential market, says its CEO.
BY LOUISE WENDT JENSEN Offentliggjort 29.03.17 kl. 15:02
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.
The small Danish biotech company Mipsalus is on the prowl for a partner to help it bring its drug to treat the hereditary metabolic condition phenylketonuria (PKU) into the clinic and onto the market as fast as possible.
Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes.
Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.
Det europæiske ekspertpanel CHMP havde travlt på deres aprilmøde i fredags, hvor der blev givet grønt lys for seks nye originale lægemidler og fem kopiversioner af allerede godkendte. Der var også udvidede godkendelser at hente for tre midler.
Optimisme omkring fremtidig vækst og øgede markedsandele, får Jyske Bank til både at hæve anbefalingen og kursmålet på Coloplast. Dagens opkøb af Coloplasts amerikanske konkurrent understreger potentialet i sektoren, vurderer man hos Sydbank.